Alpha Tau Medical (DRTS) news
Recent news
Alpha Tau Medical - to pursue dual listing on Nasdaq and Tel Aviv Stock Exchange
AInvest Wire · Aug 10, 2026Alpha Tau Medical - no serious Alpha Dart-associated adverse events; only two Grade 1 events reported
AInvest Wire · Jul 21, 2026Alpha Tau Medical CFO Raphi Levy reports open market sale of 20,000 ordinary shares on June 30 at $12/share - SEC filing
On June 30, 2026, Raphi Levy, Chief Financial Officer of Alpha Tau Medical Ltd (DRTS), executed an open market sale of 20,000 ordinary shares at a price of $12 per share, according to a recent SEC filing. The transaction was disclosed through a Form 4 filing, which is standard for reporting insider…
AInvest Wire · Jul 1, 2026Barclays raises target price to $17 from $15 for Alpha Tau
Barclays has raised its price target for Alpha Tau Medical Ltd. (NASDAQ:DRTS) to $17 from $15, maintaining an overweight rating . The firm highlighted the company’s recent progress in clinical trials and its potential for regulatory approval in the coming years. Alpha Tau Medical, a biomedical…
AInvest Wire · Jun 4, 2026Alpha Tau Medical - Tolmar to invest additional $10M and up to $96.5M in milestones if bladder option exercised
AInvest Wire · Jun 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.